ZS Launches ZAIDYN™ Clinical Development, Expanding Its Digital Life Sciences Platform
17.6.2022 16:45:00 EEST | Business Wire | Press release
Global management consulting and technology firm ZS has announced the launch of ZAIDYN Clinical Development. The offering is the latest expansion of the platform ZAIDYN by ZS, designed to empower life sciences companies to digitally transform and scale customer engagement, field performance, analytics and—now—clinical development design and planning.
“Today, we’re announcing the launch of ZAIDYN Clinical Development, expanding on more than 35 years of software expertise,” said Sanjay Joshi, managing principal and platform lead for ZS. “With ZAIDYN, life sciences organizations can connect their global teams, products, processes, applications, algorithms and data assets for powerful insights to shape clinical research and accelerate clinical development timelines. Our platform works with existing IT systems to fuel efficiency and connectivity, reduce costs and empower life sciences companies of all sizes to innovate, scale and grow as the global healthcare ecosystem evolves.”
ZAIDYN Clinical Development harnesses the power of a self-learning network, AI-driven insights and algorithms to create a fluid, fast, frictionless trial experience for business users, site investigators and patients. With our products, companies have the power to:
- Drive innovation and decision-making throughout the clinical development process with insightful, dynamic reporting and analytics for clinical teams and a high-level view of clinical trial operations for leaders
- Optimize clinical study planning and protocol design using AI and predictive insights that reflect the experiences and perspectives of participants and patients
- Empower teams to test and model site and enrollment scenarios to find ways to make studies more inclusive and engaging, lift participant burden, limit amendments and accelerate trial efficiency
- Create an expanding universe of industry and historical clinical trial data, real-world data, site criteria and patient survey insights
- Raise the bar for clinical research with products built on Amazon Web Services (AWS) that apply the latest clinical data standards and fuel connectivity throughout upstream and downstream systems
More than 130 companies already use ZS’s products to drive business decisions. Now, these companies can combine the clinical expertise of ZS consulting with the latest features of ZAIDYN Clinical Development to break down business and clinical silos and empower teams to work together more efficiently.
“ZAIDYN Clinical Development will help our clients navigate the large-scale, disruptive changes we see happening across our industry—and those on the horizon as AI and machine learning transform clinical research and development (R&D),” said Aaron Mitchell, ZS’s global R&D excellence practice leader. “Smarter platforms for life sciences can help us improve clinical trial diversity, bring life-saving therapies to patients faster, and unlock patterns and breakthroughs that will transform the future of clinical research. It’s all about using insights from data more effectively to drive more inclusive studies and better patient outcomes.”
“With the support of ZS and the ZAIDYN platform, we’re accelerating the transformation we initiated three years ago,” reflected Cynthia Deparis, program manager at Sanofi. “The platform is helping us take a data-driven approach to identifying the best countries and sites for clinical studies. It’s helped us integrate and expand the universe of clinical operational trial data so we can target sites and countries that help us deliver on our development portfolio and think through various strategic parameters like the competitive landscape, our peers’ activity, historical knowledge about sites and feedback from outreached sites. With these insights and the ability to model different scenarios, we can continue to optimize recruitment and enhance the accuracy of our projections, setting our clinical trial development on a continuous improvement cycle.”
About ZS
ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005012/en/
Contact information
Quintin Maidment; ZS@theblissgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 10:15:00 EEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom